抗線溶薬の世界市場:疾患別(婦人科、遺伝性血管浮腫、線溶反応試験、手術、その他)、エンドユーザー別(病院&クリニック、外来手術センター、医療専門プロセス)...市場調査レポートについてご紹介

【英文タイトル】Antifibrinolytic Drugs Market by Indication (Gynecology, Hereditary Angiedema, Fibrinolytic Response Testing, Surgeries, and Others) and End user (Hospitals & Clinics, Ambulatory Surgical Centers, and Healthcare Specialty Process): Global Opportunity Analysis and Industry Forecast, 2019–2026

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

Chapter 1: Introduction

1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.4. Research Methodology

1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models

Chapter 2: Executive Summary

2.1. Key Findings of The Study
2.2. Cxo Perspective

Chapter 3: Market Overview

3.1. Market Definition And Scope
3.2. Key Findings

3.2.1. Top Investment Pockets

3.3. Porter’S Five Forces Analysis

3.3.1. Moderate Bargaining Power of Buyers
3.3.2. Low Bargaining Power of Suppliers
3.3.3. Moderate Threat of Substitutes
3.3.4. Low Threat of New Entrants
3.3.5. Moderate Competitive Rivalry

3.4. Top Player Positioning
3.5. Market Dynamics

3.5.1. Drivers

3.5.1.1. Surge In Severe Road Accidents
3.5.1.2. Significant Increase In Surgical Procedures

3.5.2. Restraint

3.5.2.1. High Cost of These Drugs

3.5.3. Opportunity

3.5.3.1. Various Growth Opportunities In Emerging Economies

Chapter 4: Antifibrinolytic Drugs Market, By Indication

4.1. Overview

4.1.1. Market Size And Forecast

4.2. Gynecology

4.2.1. Key Market Trends And Opportunities
4.2.2. Market Size And Forecast
4.2.3. Market Share Analysis, By Country

4.3. Hereditary Angioedema

4.3.1. Key Market Trends And Growth Opportunities
4.3.2. Market Size And Forecast
4.3.3. Market Share Analysis, By Country

4.4. Fibrinolytic Response Testing

4.4.1. Key Market Trends And Opportunities
4.4.2. Market Size And Forecast
4.4.3. Market Share Analysis, By Country

4.5. Surgeries

4.5.1. Key Market Trends And Opportunities
4.5.2. Market Size And Forecast
4.5.3. Market Share Analysis, By Country

4.6. Others

4.6.1. Key Market Trends And Opportunities
4.6.2. Market Size And Forecast
4.6.3. Market Share Analysis, By Country

Chapter 5: Antifibrinolytic Drugs Market, By End User

5.1. Overview

5.1.1. Market Size And Forecast

5.2. Hospitals

5.2.1. Market Size And Forecast
5.2.2. Market Share Analysis, By Country

5.3. Ambulatory Surgery Centers

5.3.1. Market Size And Forecast
5.3.2. Market Share Analysis, By Country

5.4. Trauma Centers

5.4.1. Market Size And Forecast
5.4.2. Market Share Analysis, By Country

Chapter 6: Antifibrinolytic Drugs Market, By Region

6.1. Overview

6.1.1. Market Size And Forecast

6.2. North America

6.2.1. Key Market Trends And Opportunities
6.2.2. Market Size And Forecast, By Country
6.2.3. Market Size And Forecast, By Indication
6.2.4. Market Size And Forecast, By End User
6.2.5. U.S.

6.2.5.1. U.S. Market Size And Forecast, By Indication
6.2.5.2. U.S. Market Size And Forecast, By End User

6.2.6. Canada

6.2.6.1. Canada Market Size And Forecast, By Indication
6.2.6.2. Canada Market Size And Forecast, By End User

6.2.7. Mexico

6.2.7.1. Mexico Market Size And Forecast, By Indication
6.2.7.2. Mexico Market Size And Forecast, By End User

6.3. Europe

6.3.1. Key Growth Factors And Opportunities
6.3.2. Market Size And Forecast, By Country
6.3.3. Market Size And Forecast, By Indication
6.3.4. Market Size And Forecast, By End User
6.3.5. Germany

6.3.5.1. Germany Market Size And Forecast, By Indication
6.3.5.2. Germany Market Size And Forecast, By End User

6.3.6. France

6.3.6.1. France Market Size And Forecast, By Indication
6.3.6.2. France Market Size And Forecast, By End User

6.3.7. Uk

6.3.7.1. Uk Market Size And Forecast, By Indication
6.3.7.2. Uk Market Size And Forecast, By End User

6.3.8. Italy

6.3.8.1. Italy Market Size And Forecast, By Indication
6.3.8.2. Italy Market Size And Forecast, By End User

6.3.9. Rest of Europe

6.3.9.1. Rest of Europe Market Size And Forecast, By Indication
6.3.9.2. Rest of Europe Market Size And Forecast, By End User

6.4. Asia-Pacific

6.4.1. Key Growth Factors And Opportunities.
6.4.2. Market Size And Forecast, By Country
6.4.3. Market Size And Forecast, By Indication
6.4.4. Market Size And Forecast, By End User
6.4.5. Japan

6.4.5.1. Japan Market Size And Forecast, By Indication
6.4.5.2. Japan Market Size And Forecast, By End User

6.4.6. China

6.4.6.1. China Market Size And Forecast, By Indication
6.4.6.2. China Market Size And Forecast, By End User

6.4.7. India

6.4.7.1. India Market Size And Forecast, By Indication
6.4.7.2. India Market Size And Forecast, By End User

6.4.8. Rest of Asia-Pacific

6.4.8.1. Rest of Asia-Pacific Market Size And Forecast, By Indication
6.4.8.2. Rest of Asia – Pacific Market Size And Forecast, By End User

6.5. Lamea

6.5.1. Key Growth Factors And Opportunities
6.5.2. Market Size And Forecast, By Country
6.5.3. Market Size And Forecast, By Indication
6.5.4. Market Size And Forecast, By End User
6.5.5. Brazil

6.5.5.1. Brazil Market Size And Forecast, By Indication
6.5.5.2. Brazil Market Size And Forecast, By End User

6.5.6. Saudi Arabia

6.5.6.1. Saudi Arabia Market Size And Forecast, By Indication
6.5.6.2. Saudi Arabia Market Size And Forecast, By End User

6.5.7. South Africa

6.5.7.1. South Africa Market Size And Forecast, By Indication
6.5.7.2. South Africa Market Size And Forecast, By End User

6.5.8. Rest of Lamea

6.5.8.1. Rest of Lamea Market Size And Forecast, By Indication
6.5.8.2. Rest of Lamea Market Size And Forecast, By End User

Chapter 7: Company Profiles

7.1. Akorn Inc.

7.1.1. Company Overview
7.1.2. Company Snapshot
7.1.3. Operating Business Segments
7.1.4. Product Portfolio
7.1.5. Business Performance

7.2. Aurobindo Pharma Limited

7.2.1. Company Overview
7.2.2. Company Snapshot
7.2.3. Operating Business Segments
7.2.4. Product Portfolio
7.2.5. Business Performance

7.3. Bayer Ag

7.3.1. Company Overview
7.3.2. Company Snapshot
7.3.3. Operating Business Segments
7.3.4. Product Portfolio
7.3.5. Business Performance

7.4. Ferring Holding Sa

7.4.1. Company Overview
7.4.2. Company Snapshot
7.4.3. Operating Business Segments
7.4.4. Product Portfolio
7.4.5. Business Performance

7.5. Mylan N.V.

7.5.1. Company Overview
7.5.2. Company Snapshot
7.5.3. Operating Business Segments
7.5.4. Product Portfolio
7.5.5. Business Performance

7.6. Novartis International Ag (Sandoz)

7.6.1. Company Overview
7.6.2. Company Snapshot
7.6.3. Operating Business Segments
7.6.4. Product Portfolio
7.6.5. Business Performance

7.7. Pfizer Inc.

7.7.1. Company Overview
7.7.2. Company Snapshot
7.7.3. Operating Business Segments
7.7.4. Product Portfolio
7.7.5. Business Performance

7.8. Sanofi S.A.

7.8.1. Company Overview
7.8.2. Company Snapshot
7.8.3. Operating Business Segments
7.8.4. Product Portfolio
7.8.5. Business Performance

7.9. Takeda Pharmaceutical Company Limited

7.9.1. Company Overview
7.9.2. Company Snapshot
7.9.3. Operating Business Segments
7.9.4. Product Portfolio
7.9.5. Business Performance

7.10. Vitruvias Therapeutics Inc.

7.10.1. Company Overview
7.10.2. Company Snapshot
7.10.3. Operating Business Segments
7.10.4. Product Portfolio
7.10.5. Business Performance
7.10.1. Key Strategic Moves And Developments


【レポート販売概要】

■ タイトル:抗線溶薬の世界市場:疾患別(婦人科、遺伝性血管浮腫、線溶反応試験、手術、その他)、エンドユーザー別(病院&クリニック、外来手術センター、医療専門プロセス)
■ 英文:Antifibrinolytic Drugs Market by Indication (Gynecology, Hereditary Angiedema, Fibrinolytic Response Testing, Surgeries, and Others) and End user (Hospitals & Clinics, Ambulatory Surgical Centers, and Healthcare Specialty Process): Global Opportunity Analysis and Industry Forecast, 2019–2026
■ 発行日:2019年12月21日
■ 調査会社:Allied Market Research
■ 商品コード:AMR20FE017
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。